BioXcel Therapeutics (BTAI) Restructuring Costs (2023 - 2025)

BioXcel Therapeutics has reported Restructuring Costs for 3 years, with the latest figure at $194000.0 in Q3 2025.

• On a quarterly basis, Restructuring Costs fell 87.51% year-over-year to $194000.0 in Q3 2025; TTM through Dec 2025 was $227000.0, a 90.7% decrease from a year earlier, with the FY2025 full-year figure at $194000.0, down 92.05% from the prior year.
• Restructuring Costs was $194000.0 for Q3 2025 at BioXcel Therapeutics, up from $33000.0 in the prior quarter.
• The five-year high for Restructuring Costs was $4.2 million in Q3 2023, with the low at $33000.0 in Q4 2024.
• Average Restructuring Costs over 3 years is $1.4 million, with a median of $856000.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Restructuring Costs sank 62.7% in 2024, then slumped 87.51% in 2025.
• Over 3 years, Restructuring Costs stood at $4.2 million in 2023, then tumbled by 99.21% to $33000.0 in 2024, then soared by 487.88% to $194000.0 in 2025.
• The last three Restructuring Costs figures came in at $194000.0 (Q3 2025), $33000.0 (Q4 2024), and $1.6 million (Q3 2024), per Business Quant data.